Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7). (February 2017) - Hirsh, V.; Park, K.; Tan, E.H.; Zhang, L.; O'Byrne, K.; Boyer, M.; Yang, J.C.H.; Mok, T.; Lee, K.H.; Lu, S.; Shi, Y.; Kim, S.W.; et al.